March 25, 2019
The oversold should rise but, futures are struggling after worries of a slowing global economy hit stocks on Friday
Attorney General Barr issued a finding’s summary of Special Prosecutor Mueller’s NO collusion or obstruction report which should relieve polarization of undercurrents in markets
Pre-open indication: BUY
News: Mesoblast (MESO; ASX:MSB) today announced its licensee in Japan, JCR Pharmaceuticals Co. Ltd., has filed to extend marketing approval of TEMCELL®1 HS Inj. for use in patients with Epidermolysis Bullosa (EB). TEMCELL is already approved for the treatment of acute graft versus host disease (aGVHD), and was the first allogeneic cellular medicine to receive full regulatory approval in Japan.
My focuses is indication analysis. An indication can be a development of almost any kind. Specifically, it may be a confirmed fact, a possible fact, or an absence of “something”, a fragment of information or even an observation!
March 19, 2019
SAGE closed down -$0.78 to $156.10 and is UP +$7.91 or 5.07% to $164.01 in the aftermarket
Zulresso is designed to reduce depression symptoms by targeting receptors of the neurotransmitter known as GABA, helping restore the normal balance in the brain that is disrupted around the time of childbirth.
March 25, 2019
As the pre-open post stated, “Oversold, there are many yet, for the lack of news – any momentum will be based on trading and sentiment which is considered a glass half full or half empty!”
Also, markets showed little reaction to the end of Special Prosecutor Mueller’s probe into the 2016 election, I believe many investors, traders and Americans are just fed up with the vitriol
Q4 and FY18 results: Cesca Therapeutics (KOOL)
Review the snapshot of the daily ‘workings” of the sector composite of cell and gene therapy companies.
March 19, 2019
SAGE closed down -$0.78 to $156.10 and is UP +$7.91 or 5.07% to $164.01 in the aftermarket Zulresso is designed to reduce depression symptoms by targeting receptors of the neurotransmitter known as GABA, helping restore the normal balance in the brain that is disrupted around the time of childbirth.
March 16, 2019
Q4/18 financial results is a scorecard of (AKA) earnings of 45 covered companies 32 out of 45 ... The current LPS (loss per share) or net income, cash positions i.e. "runways" and correlation of "street" expectations - it's a reflection of this universe's investing "status"
March 12, 2019
OSIR is up +$0.14 or +0.74% to $19.02 having closed at $18.88 This offer represents a 37% premium to its 90-day volume-weighted average stock price
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.
© 2019 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
